Shenzhen YHLO Biotech CoSHSE:688575 +0.66%64 EBITDA Margin % is 5.59% as of Mar. 2026, which is 79% below its 10-year median of 26.17. GuruFocus rates SHSE:688575 with a GF Score™ of 64/100 and a GF Value™ of ¥14.47 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Shenzhen YHLO Biotech Co ranks worse than 50.61% on this metric.
Shenzhen YHLO Biotech Co (SHSE:688575) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shenzhen YHLO Biotech Co EBITDA Margin % Related Terms
Shenzhen YHLO Biotech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688575 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Shenzhen YHLO Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen YHLO Biotech Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen YHLO Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shenzhen YHLO Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen YHLO Biotech Co (SHSE:688575) has a EBITDA Margin % of 5.59% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shenzhen YHLO Biotech Co and its competitors. This is 79% below median its historical median of 26.17. Over the past decade, Shenzhen YHLO Biotech Co's EBITDA Margin % has ranged from 5.21 to 33.65. According to the industry distribution chart, Shenzhen YHLO Biotech Co ranks #413 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 50.6%.
Is Shenzhen YHLO Biotech Co's EBITDA Margin % too high?
Shenzhen YHLO Biotech Co's current EBITDA Margin % of 5.59% is 79% below median its 10-year median of 26.17. Over the past 10 years, this metric has ranged from a low of 5.21 to a high of 33.65. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Shenzhen YHLO Biotech Co's value of 5.59% is 25% below this industry median. Based on the distribution chart, Shenzhen YHLO Biotech Co ranks #413 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shenzhen YHLO Biotech Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen YHLO Biotech Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen YHLO Biotech Co ranks #413 out of 816 companies for EBITDA Margin %. This places Shenzhen YHLO Biotech Co in the lower half of its industry. The industry median EBITDA Margin % is 7.46. Shenzhen YHLO Biotech Co's value of 5.59% is 25% below this benchmark. Historically, Shenzhen YHLO Biotech Co's own EBITDA Margin % has ranged from 5.21 to 33.65 over the past decade. While the company's 10-year median is 26.17 vs. the industry median of 7.46, Shenzhen YHLO Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen YHLO Biotech Co's current EBITDA Margin % of 5.59% is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shenzhen YHLO Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen YHLO Biotech Co's current EBITDA Margin % is 5.59%, which is 79% below median its own 10-year median of 26.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen YHLO Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co (SHSE:688575) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥14.47, compared to a current price of ¥9.17 — trading 36.6% below its estimated fair value. The current EBITDA Margin % is 5.59%, which is 79% below median its 10-year median of 26.17 and 25% below the Medical Devices & Instruments industry median of 7.46. Shenzhen YHLO Biotech Co's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shenzhen YHLO Biotech Co (SHSE:688575), the current EBITDA Margin % is 5.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen YHLO Biotech Co (SHSE:688575) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen YHLO Biotech Co stock appears to be undervalued.
The current stock price of ¥9.17 is trading 36.6% below its estimated GF Value™ of ¥14.47.
GuruFocus considers Shenzhen YHLO Biotech Co to be Significantly Undervalued.
Key valuation signals for SHSE:688575:
EBITDA Margin %: 5.59% (79% below median its 10-year median of 26.17)
GF Value™: ¥14.47 vs. price of ¥9.17 (36.6% below fair value)
Industry Position: 25% below the Medical Devices & Instruments median (#413 of 816)
No single metric tells the full story. See the SHSE:688575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen YHLO Biotech Co Ltd is engaged in the research, development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay. Its product portfolio includes solutions based on technologies such as chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. Its products are used in diagnostic applications including autoimmunity, reproductive health, infection, liver disease, and respiratory disease testing, and are supplied to healthcare institutions and testing centers.
64GF Score
Get the complete analysis for SHSE:688575
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688575 has been successfully added to your 
